MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

T lymphocytes in Parkinson’s disease pathogenesis and therapy: A systematic review

J. Baird, J. Quinn (Portland, OR, USA)

Meeting: 2018 International Congress

Abstract Number: 1701

Keywords: Disease-modifying strategies, Inflammation, Parkinsonism

Session Information

Date: Monday, October 8, 2018

Session Title: Parkinson's Disease: Pathophysiology

Session Time: 1:15pm-2:45pm

Location: Hall 3FG

Objective: A systematic literature review was conducted to synthesize the current state of knowledge on the role of T lymphocytes in Parkinson’s disease (PD) pathology and therapy.

Background: While the mechanisms underlying the progressive, degenerative aspects of PD are not entirely clear, several lines of evidence have suggested that immune dysregulation may play a role. It is being increasingly recognized that interactions between the microglia and infiltrating T lymphocytes shape the pathogenesis of Parkinson’s disease and modulating the T cell response has resulted in neuroprotection in numerous preclinical models.

Methods: MEDLINE search was performed with the MeSH terms “t lymphocytes” and “Parkinson disease,” yielding 89 abstracts that were reviewed and screened for relevancy to the review topic. Papers that passed this screening process were reviewed in full, and other relevant publications cited in this group were added to the body of literature reviewed, for a total of 100 publications.

Results: This systematic review shows that 1) T cell regulation modulates neuroprotection in preclinical models of Parkinson’s disease (13 references), 2) PD patients can be distinguished from healthy controls by evidence of altered T cell status in peripheral blood (15 references), 3) Dopamine has important immunomodulatory effects which may confound study of T cells in patients on dopaminergic therapies (7 references). 4) Glatiramer acetate, an FDA-approved therapy for multiple sclerosis that works through modulating the T cell response, has had success in preclinical PD models and is a promising target for translation.

Conclusions: The last few decades of Parkinson’s disease research have produced an enhanced understanding of the neuroinflammatory basis for this neurodegenerative disease. The T cell response is central to many of the most promising neuroprotective therapies awaiting translation to human subjects.

To cite this abstract in AMA style:

J. Baird, J. Quinn. T lymphocytes in Parkinson’s disease pathogenesis and therapy: A systematic review [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/t-lymphocytes-in-parkinsons-disease-pathogenesis-and-therapy-a-systematic-review/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/t-lymphocytes-in-parkinsons-disease-pathogenesis-and-therapy-a-systematic-review/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley